Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CT.

ABSTRACT:

Objective

To quantify Nectin-4 expression in tumour lesions using the Nectin-4-binding peptide Gallium-68-N188 and positron emission tomography (PET)/computed tomography (CT) in patients with advanced or metastasised urothelial cancer eligible for therapy with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin, in combination with checkpoint inhibitor pembrolizumab (Ev/P).

Methods

In 10 patients, Nectin-4 PET/CT imaging was analysed before planned systemic therapy with Ev/P based on standardised uptake value (SUV) measurements and the results were correlated to available microscopic findings on Nectin-4 immunohistochemistry and to clinical follow-up.

Results

Nectin-4 PET is suitable for detecting Nectin-4 expression in tumour lesions and demonstrates het

SUBMITTER: Miederer M 

PROVIDER: S-EPMC12690338 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature